The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Wei, Zhongcao; Liu, Na; Tantai, Xinxing; Xing, Xin; Xiao, Cailan; Chen, Lirong; Wang, Jinhai

doi:10.1007/s12072-018-9910-x

Cited by 41 publications

(39 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Incomplete understanding of how curcumin exerts its effects in vivo is one of the major hurdles in developing curcumin as a therapeutic strategy, especially for diseases such as NAFLD where new treatment strategies are urgently needed. Meta-analyses of RCTs, such as the one by Wei et al [6], are an important first step to establish the beneficial effects of oral supplementation on individual metabolic parameters needed to be modified in a given disease process. Verification of several other aspects related to curcumin bioavailability and/or primary site of action ( Fig.…”

Section: Are the Beneficial Systemic/metabolic Effects Of Orally Admimentioning

confidence: 99%

“…In this issue of the Journal, Wei et al [6] report a metaanalysis of randomized controlled trials (RCTs) examining the effects of curcumin on the metabolic parameters of nonalcoholic fatty liver disease (NAFLD). Out of 99 studies identified by literature searches, only four studies met the stringent inclusion criteria namely, RCT or parallel trial, included subjects > 18 years of age, assessment of NAFLD (grades 1-3) by liver ultrasound and the fact that the intervention group received curcumin and control group received a placebo.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Curcumin as a potential therapeutic option for NAFLD and other metabolic diseases: need for establishing the underlying mechanism(s) of action

Ghosh

2019

Hepatol Int

View full text Add to dashboard Cite

Section: Are the Beneficial Systemic/metabolic Effects Of Orally Admimentioning

confidence: 99%

mentioning

confidence: 99%

Curcumin as a potential therapeutic option for NAFLD and other metabolic diseases: need for establishing the underlying mechanism(s) of action

Ghosh

2019

Hepatol Int

View full text Add to dashboard Cite

“…Panahi 2018 was a single arm and open label trial 11. All of the other included trials specified that they were randomized, double-blinded, and placebo-controlled 9,10,12-14. However, the Panahi 2017 trial allocated therapy on an alternating basis (Bottle A, then B, then A, then B, etc) instead of performing true randomization 12.…”

Section: Resultsmentioning

confidence: 99%

“…The evidence of incomplete data is indeterminate in all trials and there was no evidence of selective reporting except in the trial by Chirapongsathorn 2012 where 53 patients were reportedly enrolled but only 20 had outcome data reported 9-14. Chirapongsathorn 2012 is only available in abstract form and the length of time without a resulting publication suggests the possibility of methodological issues 9,10…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials

White¹,

Lee²

2019

Pharm Pract (Granada)

View full text Add to dashboard Cite

Background: Turmeric and its curcumin extract have been evaluated in patients with nonalcoholic fatty liver disease (NAFLD), a common ailment that can lead to irreparable liver damage. Objective: To identify the evidence supporting the use of turmeric or curcumin therapy in NAFLD. Methods: We searched PubMed, EMBASE, and Cochrane Central from the earliest possible date to 12/17/18 including terms for turmeric, curcumin, and NAFLD. We assessed the impact of turmeric or its curcumin extract on alanine transaminase (ALT), aspartate transaminase (AST), and NAFLD severity via ultrasound. Results: Five trials assessed the comparative efficacy of curcumin/turmeric in NAFLD. One trial was single armed with comparisons only versus baseline and another trial was only available in abstract form. All of the trials had small sample sizes, 4 of 5 trials had limited durations of follow-up, and all trials had methodological limitations that negatively impacted the strength and applicability of evidence. Clinical and methodological heterogeneity precluded statistical pooling. Three of the 4 trials with evaluable data for turmeric or curcumin versus their own baseline demonstrated significant reductions in ALT, AST, and NAFLD severity grade. Two of the 4 placebo controlled trials had significant mean difference reductions in ALT and AST for turmeric or curcumin versus placebo while 2 of 3 of these trials found significant reductions in NAFLD severity grade. Among these trials, only one used turmeric instead of a curcumin extract and this turmeric trial did not demonstrate any differences in ALT, AST, or NAFLD severity between the turmeric and placebo groups. Conclusions: Curcumin extract is a promising, but not proven, treatment for NAFLD while the role for turmeric is less clear. The general findings are that ALT, AST and NAFLD severity are reduced with the use of curcumin.

show abstract

Medicinal plants and bioactive natural compounds as inhibitors ofHMG‐CoAreductase: A literature review

et al. 2020

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are one of the most important causes for mortality worldwide. Elevated levels of total cholesterol, and particularly LDL-cholesterol (LDL-C) are the main risk factor for acute myocardial infarction (AMI) and ischemic heart disease. The risk of CVDs could be reduced by decreasing the elevated cholesterol levels. β-hydroxy β-methylglutaryl-CoA reductase (HMGCoAR) is the primary and rate-limiting enzyme in the cholesterol biosynthesis pathway. Recently, the crucial role of nutraceuticals in maintaining normal physiological function was established. Nutraceuticals play an important role in preventing several non-communicable diseases such as obesity, CVDs, cancer, diabetes, and reducing hyperlipidemia. Although the effect of nutraceuticals and herbal medicine on CVDs and dyslipidemia was previously investigated thoroughly, the effect of these natural products on HMGCoAR as one of the important enzymes involved in CVDs etiopathogenesis has not yet been investigated. Therefore, the

show abstract

The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Cited by 41 publications

References 49 publications

Curcumin as a potential therapeutic option for NAFLD and other metabolic diseases: need for establishing the underlying mechanism(s) of action

Curcumin as a potential therapeutic option for NAFLD and other metabolic diseases: need for establishing the underlying mechanism(s) of action

The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials

Medicinal plants and bioactive natural compounds as inhibitors ofHMG‐CoAreductase: A literature review

Contact Info

Product

Resources

About